Back to Journals » Drug Design, Development and Therapy » Volume 13

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Total article views   HTML views PDF downloads Totals
8,801 Dovepress* 7,889+ 1,230 9,119
PubMed Central* 912 155 1,067
Totals 8,801 1,385 10,186
*Since 24 January 2019

View citations on PubMed Central and Google Scholar